ArticleJournal of molecular histology2025
Decoding phillygenin's dual attack on breast cancer: ferroptosis induction and immune evasion suppression.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis and immune evasion are pivotal mechanisms in the pathogenesis of breast cancer (BC), making them promising therapeutic targets. Phillygenin (PHI), a lignan compound derived from Forsythiae Fructus, has demonstrated broad pharmacological properties, including anti-tumor effects. To discuss the impact of PHI on BC. The study examined PHI's anti-tumor properties and mechanisms using CCK-8 assays, biochemical analyses, DCHF-DA staining, ELISA, immunofluorescence, and western blot techniques. Tumor-bearing mice were utilized for studies in vivo, with tumor tissues being analyzed by H&E staining, immunohistochemistry, and western blotting. The viability of MDA-MB-231 and MCF7 cells was notably repressed by PHI, with respective IC50 values of 81.44 µM and 95.72 µM. PHI elevated intracellular Fe
Indexed as
Identifiers
40694249What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.